Biogen Idec 8-K 2007
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 18, 2007
Biogen Idec Inc.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code (617) 679-2000
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Item 7.01 Regulation FD Disclosure.
On June 18, 2007, the registrant is presenting a Powerpoint slide showing a TYSABRI® (natalizumab) utilization and safety update at a symposium at the European Neurological Society meeting in Rhodes, Greece. A copy of the slide is furnished as Exhibit 99.1 and is incorporated herein by reference.
The Powerpoint slide is being furnished pursuant to Item 7.01 of this Current Report on Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
Item 9.01 Financial Statements and Exhibits.
99.1 Powerpoint slide showing a Tysabri utilization and safety update
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 18, 2007